Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VRAX Stock Forecast 2026-2027
$6.36
Current Price
$5.07M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VRAX Price Targets
+293.1%
To High Target of $25.00
+293.1%
To Median Target of $25.00
+293.1%
To Low Target of $25.00
VRAX Price Momentum
+103.2%
1 Week Change
+43.6%
1 Month Change
-71.4%
1 Year Change
-26.5%
Year-to-Date Change
-77.7%
From 52W High of $28.50
+154.4%
From 52W Low of $2.50
📊 TOP ANALYST CALLS
Did VRAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Virax Biolabs is one of their latest high-conviction picks.
Latest VRAX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, VRAX has a bullish consensus with a median price target of $25.00 (ranging from $25.00 to $25.00). The overall analyst rating is N/A (N/A/10). Currently trading at $6.36, the median forecast implies a 293.1% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRAX Analyst Ratings
1
Buy
0
Hold
0
Sell
VRAX Price Target Range
Low
$25.00
Average
$25.00
High
$25.00
Current: $6.36
Latest VRAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $1.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A |
Virax Biolabs Group Ltd. (VRAX) Competitors
The following stocks are similar to Virax Biolabs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Virax Biolabs Group Ltd. (VRAX) Financial Data
Virax Biolabs Group Ltd. has a market capitalization of $5.07M with a P/E ratio of -3.9x. The company generates $12,423 in trailing twelve-month revenue with a -838.2% profit margin.
Revenue growth is +684.9% quarter-over-quarter, while maintaining an operating margin of -35,264.9% and return on equity of -78.6%.
Valuation Metrics
Market Cap
$5.07M
Enterprise Value
$-4,585,396
P/E Ratio
-3.9x
PEG Ratio
-0.5x
Price/Sales
204.0x
Growth & Margins
Revenue Growth (YoY)
+684.9%
Gross Margin
N/A
Operating Margin
-35,264.9%
Net Margin
-838.2%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+176.9%
Current Ratio
10.0x
Debt/Equity
5.6x
ROE
-78.6%
ROA
-54.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Virax Biolabs Group Ltd. (VRAX) Business Model
About Virax Biolabs Group Ltd.
What They Do
Develops diagnostic testing kits for viral diseases.
Business Model
Virax Biolabs generates revenue by developing and distributing diagnostic testing kits and related healthcare solutions aimed at detecting viral pathogens. The company targets various sectors, including healthcare institutions, government departments, and research organizations, ensuring a broad customer base and consistent demand for its innovative products.
Additional Information
Virax Biolabs plays a crucial role in public health, particularly during global health crises, by providing essential tools for early detection and management of infectious diseases. Their focus on advancing medical diagnostics is vital for enhancing healthcare systems' ability to respond to viral threats.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
19
CEO
Mr. James Foster
Country
United Kingdom
IPO Year
2022
Website
viraxbiolabs.comVirax Biolabs Group Ltd. (VRAX) Latest News & Analysis
Latest News
Quick Summary
Virax Biolabs Group Limited (NASDAQ: VRAX) approved a 1-for-25 share consolidation effective June 26, 2026, following shareholder approval on June 12, 2026.
Why It Matters
Virax Biolabs' 1-for-25 share consolidation reduces the number of shares outstanding, potentially increasing share price and signaling management's confidence, impacting market perception and liquidity.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs (NASDAQ: VRAX) announced positive early results for its ViraxImmune™ test for Long COVID and related syndromes, showing 88% specificity and 92% positive predictive value, supporting further development.
Why It Matters
Positive pilot data for ViraxImmune™ suggests strong potential for diagnosing Long COVID and related conditions, enhancing the company's value and attracting investor interest in healthcare innovation.
Source: PRNewsWire
Market Sentiment:
Neutral
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
2 months ago
Quick Summary
Virax Biolabs is pursuing a focused strategy on ViraxImmune™ and plans to enter the U.S. market, highlighting a strong balance sheet and recent operational progress.
Why It Matters
Virax Biolabs’ strategy to enter the U.S. market and its strong financial position may indicate potential undervaluation, signaling growth opportunities for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
What's Behind The Jump In Virax Biolabs Stock?
3 months ago
Quick Summary
Virax Biolabs' subsidiary has received ISO 13485:2016 and ISO 9001:2015 certifications for its quality management system from LRQA, enhancing its compliance and operational credibility.
Why It Matters
ISO certifications enhance credibility and operational efficiency, potentially increasing investor confidence and attracting partnerships, which can positively impact Virax Biolabs' market position.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Virax Biolabs Group's subsidiary received ISO 13485:2016 and ISO 9001:2015 certifications for its quality management system, valid until February 2029.
Why It Matters
ISO certifications enhance Virax's credibility and operational efficiency, potentially leading to increased market trust, new partnerships, and better sales, positively impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Virax Biolabs Group Limited (VRAX) has received a Zacks Rank #2 (Buy), indicating heightened optimism regarding its earnings prospects.
Why It Matters
Growing optimism and a Zacks Rank #2 upgrade suggest potential earnings growth for Virax Biolabs, indicating a favorable investment opportunity and possible stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About VRAX Stock
What is Virax Biolabs Group Ltd.'s (VRAX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Virax Biolabs Group Ltd. (VRAX) has a median price target of $25.00. The highest price target is $25.00 and the lowest is $25.00.
Is VRAX stock a good investment in 2027?
According to current analyst ratings, VRAX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRAX stock?
Wall Street analysts predict VRAX stock could reach $25.00 in the next 12 months. This represents a 293.1% increase from the current price of $6.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Virax Biolabs Group Ltd.'s business model?
Virax Biolabs generates revenue by developing and distributing diagnostic testing kits and related healthcare solutions aimed at detecting viral pathogens. The company targets various sectors, including healthcare institutions, government departments, and research organizations, ensuring a broad customer base and consistent demand for its innovative products.
What is the highest forecasted price for VRAX Virax Biolabs Group Ltd.?
The highest price target for VRAX is $25.00 from at , which represents a 293.1% increase from the current price of $6.36.
What is the lowest forecasted price for VRAX Virax Biolabs Group Ltd.?
The lowest price target for VRAX is $25.00 from at , which represents a 293.1% increase from the current price of $6.36.
What is the overall VRAX consensus from analysts for Virax Biolabs Group Ltd.?
The overall analyst consensus for VRAX is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are VRAX stock price projections?
Stock price projections, including those for Virax Biolabs Group Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 10, 2026 4:07 AM UTC